Form4insider filings, from the source

SEC Form 4 · accession 0001645627-17-000110

ENDONOVO THERAPEUTICS, INC. · ENDV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Scott Mann
Officer — President · 10% Owner
Period of report
Aug 21, 2017
Accepted (ET)
Aug 25, 2017 · 7:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockAug 21, 2017P3,000$0.0288A22,533,889D
Common StockAug 21, 2017P5,000$0.025A22,538,889D
Common StockAug 21, 2017P5,000$0.025A22,543,889D
Common StockAug 21, 2017P5,000$0.0265A22,548,889D
Common StockAug 21, 2017P3,000$0.0268A22,551,889D
Common StockAug 21, 2017P3,000$0.0279A22,554,889D
Common StockAug 21, 2017P5,000$0.0275A22,559,889D
Common StockAug 21, 2017P3,000$0.0273A22,562,889D
Common StockAug 21, 2017P5,000$0.0271A22,567,889D
Common StockAug 21, 2017P5,000$0.0271A22,572,889D
Common StockAug 21, 2017P3,000$0.0262A22,575,889D
Common StockAug 22, 2017P3,000$0.0254A22,578,889D
Common StockAug 22, 2017P3,000$0.0255A22,581,889D
Common StockAug 22, 2017P3,000$0.0254A22,584,889D
Common StockAug 22, 2017P3,000$0.0256A22,587,889D
Common StockAug 22, 2017P3,000$0.0256A22,590,889D
Common StockAug 22, 2017P3,000$0.0256A22,593,889D
Common StockAug 22, 2017P3,000$0.0256A22,596,889D
Common StockAug 22, 2017P5,000$0.0255A22,601,889D
Common StockAug 23, 2017P3,000$0.0255A22,604,889D
Common StockAug 23, 2017P3,000$0.0248A22,607,889D
Common StockAug 23, 2017P5,000$0.0248A22,612,889D
Common StockAug 23, 2017P3,000$0.0247A22,615,889D
Common StockAug 23, 2017P5,000$0.0245A22,620,889D
Common StockAug 23, 2017P2,000$0.0244A22,622,889D
Common StockAug 23, 2017P10,000$0.0246A22,632,889D
Common StockAug 23, 2017P3,000$0.0244A22,635,889D
Common StockAug 23, 2017P3,000$0.0245A22,638,898D
Common StockAug 23, 2017P3,000$0.023A22,641,889D
Common StockAug 23, 2017P3,000$0.023A22,644,889D

Table II — derivative securities

No Table II lines on this filing.